Core Insights - HEALWELL AI Inc. and WELL Health Technologies Corp. have launched WELLTRUST™, a platform designed for secure, consent-driven patient identification for clinical research within WELL-operated clinics in Canada [1][10]. Company Overview - HEALWELL AI focuses on preventative care through healthcare artificial intelligence, aiming to improve healthcare outcomes by early disease detection and clinical decision support systems [7]. - WELL Health Technologies aims to empower healthcare providers through technology, operating over 240 clinics in Canada and serving more than 43,000 healthcare providers across North America [8]. Platform Features - WELLTRUST accelerates clinical research recruitment by allowing patients to consent to future outreach for clinical trials, combining WELL's clinical footprint with HEALWELL's AI capabilities [2][10]. - The platform provides a privacy-preserving infrastructure that enables ethical patient identification and research acceleration while allowing patients to opt-out if they choose [2][11]. - WELLTRUST includes a robust governance and compliance framework to meet Canadian privacy standards, facilitating partnerships with pharmaceutical sponsors and research organizations [11]. Leadership Commentary - Dr. Alexander Dobranowski from HEALWELL emphasized the platform's commitment to responsible AI in healthcare, aiming to enhance patient access to innovations while maintaining privacy [3]. - Dr. Michael Frankel from WELL highlighted the importance of technology in improving healthcare outcomes and empowering patients to participate in research safely [5].

Core Viewpoint - HEALWELL AI Inc. is clarifying its forward-looking information regarding its strategic divestments and financial performance, emphasizing its transition to a pure-play digital SaaS and AI business focused on health systems and large enterprises globally [1][3]. Financial Performance - The company reported quarterly revenue from continuing operations of $30.4 million in Q3-2025, which annualizes to an approximate revenue run-rate of $120 million, representing a 354% increase compared to revenue of $6.7 million in Q3-2024 [11]. - HEALWELL achieved a positive Adjusted EBITDA of $0.7 million in Q3-2025, compared to an Adjusted EBITDA loss of $2.8 million in Q3-2024, marking the second consecutive quarter of positive Adjusted EBITDA [11]. Strategic Transactions - The November 3rd Release announced the completion of three strategic transactions, including the sale of two non-core businesses and the contribution of two more to a clinical research joint venture, allowing HEALWELL to focus on its core digital SaaS and AI business [3][4]. AI Capabilities and Market Positioning - HEALWELL's AI solutions have received external recognition and validation, particularly through its DARWEN™ AI platform, which specializes in extracting real-world evidence from unstructured clinical data [7][8]. - The company has been recognized for its contributions to healthcare accessibility and preventative care, winning the Prix Galien USA 2024 for Best Digital Health Startup [8]. Research Validation - HEALWELL's AI technologies have been validated through various peer-reviewed studies, demonstrating their effectiveness in automating processes and improving clinical outcomes [12].